UK markets close in 1 hour 21 minutes

Xeris Biopharma Holdings, Inc. (0A8E.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.7799+0.0499 (+2.88%)
As of 05:36PM BST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.11
52-week change 370.68%
S&P500 52-week change 323.57%
52-week high 33.2499
52-week low 30.0000
50-day moving average 32.6814
200-day moving average 32.3597

Share statistics

Avg vol (3-month) 38.76k
Avg vol (10-day) 37.56k
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 8136.52M
% held by insiders 13.74%
% held by institutions 141.72%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -37.98%
Operating margin (ttm)-22.17%

Management effectiveness

Return on assets (ttm)-8.25%
Return on equity (ttm)-324.20%

Income statement

Revenue (ttm)163.91M
Revenue per share (ttm)1.19
Quarterly revenue growth (yoy)33.90%
Gross profit (ttm)N/A
EBITDA -31.68M
Net income avi to common (ttm)-62.26M
Diluted EPS (ttm)-1.4160
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)72.45M
Total cash per share (mrq)0.52
Total debt (mrq)229.19M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.64
Book value per share (mrq)-0.05

Cash flow statement

Operating cash flow (ttm)-47.02M
Levered free cash flow (ttm)-19.62M